Pfizer He announced on Friday that he would like to try his third dose Vaccine Anticoagulant for children under the age of five, so use three doses in this age range may require new approval next year.
Within the framework Clinical trials In practice, the American pharmaceutical company selected a dose of 3 micrograms per injection for infants six months and 5 years of age.
This is 10 times less than that given to adults (30 micrograms) and less than that given to children aged 5 to 11 years (10 micrograms).
In children 2 years and 5 years of age, the 10-microgram dose caused more fever than in older children, which prompted the company to select a lower dose.
But with two 3-microgram injections, their immunity is less effective than that of vaccinated adolescents and young adults.
Pfizer They then decided to change the protocol of their clinical trials Third dose, Injected “second after at least two months”, the company said in a statement.
The first two doses should be taken three weeks apart.
Booster dose has actually been shown to improve safety in older population groups.
Booster dose for minors
Katherine Johnson, chair of the inquiry, said in a conference call that the “adjustment” would not affect the schedule for the second quarter of 2022. Vaccines In Pfizer.
Pfizer Has also been announced Clinical trials For a booster dose (10 or 30 micrograms) for 600 adolescents between 12 and 17 years of age.
In fact To usIn addition to adults, the booster dose is only approved for adolescents between the ages of 16 and 17.
(With information from AFP)
All newsletter about corona virus
The COVID-19 Keeps everyone on alert. Registration All about the corona virus in our newsletter, where you can find the most relevant daily data on the progress of the virus and the fight against its spread in the country and the world.
– ‘Very clear’: What efforts are the authorities making to end violence against women in Peru?
. “Infuriatingly humble alcohol fan. Friendly entrepreneur. Travel aficionado. Typical tv advocate.”